|
|
Background: Long noncoding RNAs (lncRNAs) are a novel type of endogenous noncoding RNA that are involved in the regulation of gene expression and play important roles in several types of cancer. LncRNA001089 is an intergenic lncRNA associated with cancer progression and tumor occurrence; however, the role and function of LncRNA001089 in glioma remains unclear.
Methods: In this study, we determined the expression levels of LncRNA001089 in tissues of glioma patients and explored its effect on glioma cell metastasis and proliferation using U251 glioma cell lines. Quantitative real-time PCR (qRT-PCR) technology was used to verify the expression levels of LncRNA001089 in the 127 tissues of glioma patients. Functional studies of LncRNA001089 were performed in glioma cells, including a colony formation assay, evaluation of proliferation by CCK-8, evaluation of apoptosis by flow cytometry, and evaluation of migration and invasion in vitro by Transwell assays. Tumorigenesis was evaluated in vivo in nude mice.
Results: LncRNA001089 was downregulated in glioma tissues, evaluated by qRT-PCR. Kaplan-Meier analysis indicated that the downregulation of LncRNA001089 expression was associated with poor prognoses in glioma patients. Multivariate analysis demonstrated that LncRNA001089 downregulation and WHO high-grade glioma were independent factors that both predicted poor outcomes for glioma patients. Cells with LncRNA001089 stable overexpression exhibited decreased capacities for proliferation, migration, and invasion in vitro, and restrained nude mouse tumorigenesis in vivo, but LncRNA001089 overexpression enhanced apoptosis.
Conclusions: Our data suggest that LncRNA001089 plays a critical role in the development of glioma and may function as a potential novel biomarker and/or a therapeutic target for treatment of glioma.
DOI: 10.7754/Clin.Lab.2018.180817
|
